Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double Blind, Parallel Dose Ranging Study of Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

NCT00095732 is registered in ClinicalTrials.gov with Anthera Pharmaceuticals as lead sponsor.

NCT NCT00095732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00095732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double Blind, Parallel Dose Ranging Study of Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
Lead sponsor
Anthera Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2004
Completion date
March 31, 2005
Enrollment
129 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis, pancreatic insufficiency